Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 7/20 | 0.44 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19805136 | 0.81 | LIMK1 (0.71) | LIMK1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL20467172 | 0.81 | LIMK1 (0.52) | LIMK1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL1164810 | 0.74 | LIMK1 (0.52) | LIMK1NPC1RAB9AALDH1A1L3MBTL1 | |
| SCHEMBL4892520 | 0.73 | LIMK1 (0.72) | LIMK1NPC1RAB9AALDH1A1MEN1 | |
| SCHEMBL29506378 | 0.71 | MEN1 (0.50) | RAB9AALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2534139 | 0.71 | LIMK1 (0.44) | LIMK1RAB9AMEN1KMT2AMAPT | |
| SCHEMBL20256401 | 0.71 | MEN1 (0.50) | RAB9AALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18853655 | 0.71 | CYP1B1 (0.40) | NPC1RAB9AALDH1A1L3MBTL1MAPT | |
| SCHEMBL4901470 | 0.70 | LIMK1 (1.00) | LIMK1NPC1RAB9AALDH1A1HPGD | |
| SCHEMBL11479791 | 0.70 | LIMK1 (0.52) | LIMK1NPC1RAB9AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2019-10-31 | — | — | US | disclosed |
| WO-2018142365-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018017874-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11339178-B2 | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof | GUSB, ENGASE, MGAM | LIMK1 3876/4885NPC1 1196/4885RAB9A 3741/4885 |
| US-20190330237-A1 | INHIBITORS OF MICROBIAL BETA-GLUCURONIDASE ENZYMES AND USES THEREOF | GUSB, ENGASE, MGAM | LIMK1 3876/4885NPC1 1196/4885RAB9A 3741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.